• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, June 17, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

A breath of fresh air for emphysema research

Bioengineer by Bioengineer
July 19, 2021
in Biology
Reading Time: 3 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Department of Immune Regulation,TMDU

Tokyo, Japan – Chronic obstructive pulmonary disease (COPD) causes illness and death worldwide. It is characterized by destruction of the walls of tiny air sacs in the lungs, known as emphysema, and a decline in lung function. Little has been known about the mechanisms by which it begins to develop. But now, researchers from Japan have found a protein that promotes the development of the early stages of emphysema, with the potential to be a therapeutic target.

COPD can be triggered by environmental factors such as cigarette smoking that result in lung inflammation. The development of inflammation involves the movement of molecules inside cells, and this “intracellular trafficking” is known to be associated with some diseases. The team searched for COPD-related proteins that are involved in trafficking and identified a protein called FCHSD1, which is associated with some diseases but with no currently known role in lung function.

It is possible to create a mouse model of emphysema by treating mice with an enzyme called elastase. The team developed a mouse line that was missing the FCHSD1 protein and studied the responses of these mice in comparison with normal mice when emphysema was induced. Normal mice showed a large increase in FCHSD1 after treatment, while mice lacking FCHSD1 were protected from the development of emphysema. These mice showed less airspace expansion owing to damage to the air sacs in the lungs, and had less inflammation and cell death, known as apoptosis.

The researchers went on to investigate the molecular mechanism by which FCHSD1 acts. A protein called NRF2 moves into the nucleus in response to stress and acts to defend against it. However, FCHSD1 binds to NRF2 and prevents it moving into the nucleus. “Mice with a FCHSD1 deficiency showed enhanced nuclear translocation of NRF2 and a smaller reduction in SIRT1 levels, which is seen to occur as emphysema develops,” explains lead author Takahiro Kawasaki, “and this reduced inflammation and apoptosis of lung cells.”

A potential therapy for COPD could therefore be to increase the activity of NRF2 to counteract FCHSD1. There are treatments currently available that target NRF2, and it may be that inhibiting FCHSD1 at the same time as targeting NRF2 could make these treatments more effective and prevent systemic complications. “Our findings may also lead to a specific therapeutic strategy to ameliorate, or even halt, the progression of emphysema by inhibiting FCHSD1,” says Takashi Satoh, senior author of the paper.

COPD is a highly significant disease. The discovery of this mechanism by which FCHSD1 acts to promote the development of emphysema could lead to new treatments for many people.

###

The authors declare no competing interests. This work was supported by: the Japan Science and Technology Agency (JST) through funding for Specially Promoted Research (15H05704), a Grant-in-Aid for Young Scientists (A) (16H06234), a Grant-in-Aid for Challenging Exploratory Research (T17K195570), and a Grant-in-Aid for Scientific Research on Innovative Areas (18H05032); the Visionary Research Fund from Takeda Science Foundation and the Joint research chair of innate immunity supported by Otsuka Pharmaceutical Co., Ltd.; PRIME (17gm6110002h0001), ACT-M (17im0210108h0001), and the Research Program on Hepatitis (18fk0310106h0002 and 1 18fk0210041h0001) from the Japan Agency for Medical Research and Development, AMED.

The article, “Loss of FCHSD1 leads to amelioration of chronic obstructive pulmonary disease”, was published in PNAS at DOI: 10.1073/pnas.2019167118.

Media Contact
Takashi Satoh
[email protected]

Original Source

https://www.tmd.ac.jp/english/press-release/20210628-2/

Related Journal Article

http://dx.doi.org/10.1073/pnas.2019167118

Tags: Cell BiologyMedicine/HealthMolecular BiologyMortality/LongevityPulmonary/Respiratory Medicine
Share13Tweet8Share2ShareShareShare2

Related Posts

Diana Bernin_ ChalmersUniversityofTechnology

From Farm to Fashion: How Agricultural Waste is Transforming into Tomorrow’s Textiles

June 17, 2025
NIH Launches New Research Initiative to Investigate PFAS Effects on Male Reproductive Health

NIH Launches New Research Initiative to Investigate PFAS Effects on Male Reproductive Health

June 16, 2025

Machine Learning Advances Enable Diagnostic Testing Beyond the Lab

June 16, 2025

New Technique Breaks Fluorescence Microscopy Resolution Barrier

June 16, 2025
Please login to join discussion

POPULAR NEWS

  • Green brake lights in the front could reduce accidents

    Study from TU Graz Reveals Front Brake Lights Could Drastically Diminish Road Accident Rates

    159 shares
    Share 64 Tweet 40
  • New Study Uncovers Unexpected Side Effects of High-Dose Radiation Therapy

    76 shares
    Share 30 Tweet 19
  • Pancreatic Cancer Vaccines Eradicate Disease in Preclinical Studies

    70 shares
    Share 28 Tweet 18
  • How Scientists Unraveled the Mystery Behind the Gigantic Size of Extinct Ground Sloths—and What Led to Their Demise

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Seamlessly Connect Nanoparticles Like Building Blocks for Industrial Applications!

From Farm to Fashion: How Agricultural Waste is Transforming into Tomorrow’s Textiles

Boosting D-Lactic Acid Production Through UV Irradiation Advances

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.